Background & Aim: Traumatic brain injury is one of the main causes of death and disability. The aim of this study is to systematically review the articles which assessed some serum factors of traumatic brain injury patients in relation to their outcomes. Methods & Materials/Patients: Databases were searched for relevant publications from 2005 to 2014. Selection criteria were:Studies which evaluate the factors affecting the outcome after TBI, TBI defined as "acute changes in brain function resulting in a strong external force to the head".Resultswere measured by Glasgow Outcome Score or a comparable measure.Factors were measured in first month after injury and the prognosis was addressed. All papers were checked and approved by a specialist and expert in that field. A systematic review was performed for prognostic factors. Results: Sixty-three studies were included. Most studies used Glasgow Outcome Score at 6 months post-injury as outcome measure, sometimes in combination with other outcome measures. Strong evidence for predicting outcome was found for serum concentration of S100 protein, NSE, MBP, NF-H, GFAP, UCH-L1, blood glucose levels, serum levels of LDH, sodium level, prothrombin time, partial thromboplastin time, platelet count, D.dimer, HSP 70, serum levels of IL-8, number of circulating EPCs, and DNA levels in serum. Moderate evidence for predicting outcome was found for high serum MMP9. Strong evidence of no association was found for WBC count and serum cortisol levels. Moderate evidence of no association was found for serum total cholesterol for other determinants, inconclusive or no evidence or limited evidence was found. Conclusion: S100 protein, NSE, MBP, NF-H, GFAP, UCH-L1, blood glucose levels, serum levels of LDH, sodium level, prothrombin time, Partial thromboplastin time, platelet count, D.dimer, HSP 70, serum levels of IL-8, number of circulating EPCs, and DNA levels in serum predicted outcome after traumatic brain injury. WBC count, serum cortisol levels, total cholesterol and MMP9 did not have predictive value.
Prognostic Serum Factors in Traumatic Brain
Injury: A Systematic Review 
Introduction
Traumatic brain injury still remains a serious concern and one of the leading causes of death and disability, particularly among young adults (1, 2) . Based on studies of prevention of diseases in United States, the most common causes of traumatic brain injury include factors like traffic accidents (20%), hit a barrier (19%) and assault (11%) (1) . Traumatic brain injury can be classified into two types, primary and secondary. The primary injury occurs at the time of the accident causing direct damage to nerve tissue. Secondary damage is not seen at an early stage. Such harm is the natural and physiological response to the initial injury. Tissue hypoxia, which occurs within hours to months after the initial injury is this group (1) . Early determination of prognosis after traumatic brain injury is a priority for relatives and physicians involved in the care of these patients (2, 3) . New prognostic information beyond the clinical examination, patient demographics and radiological imaging from admission is needed to allow early prediction of short, mid, and long term outcome of patients with moderate and severe traumatic brain injury (1, 2, 3) . One of the factors involved in secondary damage that may occur following head trauma is the changes in blood parameters and biomarkers. Assessment of brain damage using biochemical tests and cerebrospinal fluid (CSF) and serum enzymes during the past decade has been done (4) . Biomarkers of structural damage such as S-100, tau, enolase Neuron Specific (NSE) and myelin basic protein (MBP) may be used as potential diagnostic tools, prognostic and therapeutic supplements (1) . The purpose of this study was to systematically review articles that studied the changes in hematological parameters in patients with traumatic brain injury and its correlation with the final outcome of treatment.of brain damage using biochemical tests, and cerebrospinal fluid (CSF) and serum enzymes during the past decade has been done (4) . Biomarkers
Study selection
Two reviewers (FS and AM or AR) independently reviewed all publications and selected eligible studies. A third author (GS) was consulted in case of disagreement. We included cohort studies and determined serum factors concentrations in patients with moderate and/or severe traumatic brain injury as defined by a Glasgow coma score<13.
Inclusion criteria were:
1. (Due to the dramatic change in measuring biomarker concentrations and the treatment of traumatic injuries in recent years), studies which were published from 2005 until 2014. 2. Studies in which, factors affecting the outcome after TBI were evaluated.
3. Studies that defined TBI as "acute changes in brain function resulting in a strong external force to the head. 4 . Studies in which the result was measured by Glasgow Outcome Score or a comparable measure describing the activity limitation and neurological state. 5 . Studies in which correlation between the measured factors in the first month after injury and the prognosis was addressed.
6. The studies population were patients with moderate and/or severe (GCS <13) TBI with or without patients with mild injury or a subgroup consisting of patients with moderate or severe TBI were analyzed separately. 7. The article was written in English or English form of it was available.
Quality Assessment
Each paper was qualitatively evaluated according to criteria intended to establish study strength. These included: 1. Twenty-five or more patients in the series with complete followup. 2. Outcomes measured -Glasgow Outcome Scale or Mortality-at six months or more.
3.Data gathered prospectively, although retrospective examination from a database creating an ongoing cohort of patients could be used. 4.Glasgow Coma Scale score measured within 24 hours. 5.Appropriate statistics (e.g. multivariate analysis) was used to include adjustment for prognostic variables.
Data Extraction
Two reviewers (FS and AM or AR) independently collected data using a standardised data abstraction form. We abstracted information related to study design, patient characteristics, treatments (operative and pharmacological), laboratory aspects of the testing factor (type of assay used, time period of sampling, and sampling type) and clinical outcomes (outcome type and timing of assessment). In instances of duplicate reporting, we used data from the study that included the largest number of patients or, when available, individual patient data from each study. We contacted authors for clarification on study sample or for missing data. If multiple measurements were carried out, we used the first measurement after the injury for analysis. If outcomes were assessed at multiple time points, we used the measurement furthest from injury for analysis. Data of studies, inclusion and exclusion criteria, number of participants, time after injury, failure to continue follow-up, measurements of outcome, prognostic factors and results of their relationships with outcome were extracted using a standardized form.
Analysis
Significant relative risk ratios (RR), odds ratios (OR) or significant correlations (P<0.05) which were introduced by studies, was used to determine levels of evidence. If multivariate analysis was performed in the study, the results of it were used to establish the level of evidence. Otherwise, the results of the univariate analysis were used (table 1) .
Results

Study selection
In total, 1021 citations were identified and after elimination of duplicates and screening and after using the inclusion and exclusion criteria, agreement was initially reached in 82 of articles and consensus was sought and finally, 63 articles were selected.
Study characteristics
The study characteristics are presented in Table 2 . All articles were written in English. The number of patients studied was from 20 to 834 individuals with moderate to severe and sometimes mild traumatic brain injury. Penetrating trauma was not mentioned.
The main measure used for prognosis was GOS (30 studies).
Other measures include mortality, GCS, ASI, PCPC, GOSE, EDSS, and DRS ( Table 2) . Most of the investigated factors were: blood glucose, serum protein S100 and NSE, as follows:16 study assessed the serum S100 protein (13 studied: S100B, 2 study: S100BB, 1 study: S100A1B), 22 study assessed the blood glucose levels and in 14 study, NSE levels were examined. 45 studies exclusively evaluated adults and 16 studies exclusively evaluated children. In other studies, age was not an entry criterion. Of all studies, in 20 studies, venous blood samples were taken. In 11 studies, arterial blood and in one study capillary blood (finger) was sampled. Other studies did not specify the sampling site.
Neuronal markers: 1. Protein S100: According to the studies, serum concentration of S100 protein is a strong prognostic factor in adults and in children and there was strong evidence of relationship between serum levels of protein S100 and outcome. 19 studies were reviewed which assessed S100 protein in the blood as a prognostic factor in TBI. In all but two studies (6, 7) , high levels associated with poor prognosis. All of these studies assessed serum levels of S100B but a study conducted in 2012 by Yousefzadeh et al. (28) evaluated the S100BB levels and Nyle'n et al. (62) studied serum levels of 3 types of this protein (S100B, S100A1B and S100BB). In studies on children with TBI (6,9,10,11,12,13) in many of them significant correlation with the prognosis of patients was achieved except a study performed by Beers et al. (2007) (6) in which a statistical correlation between serum protein and GOS at 3-4 and 6-8 months after trauma was not found. Of the studies on the adults with traumatic brain injury (7, 8, 15, 16, 17, 18, 19, 20) all except one study (7) showed significant correlation between prognosis and S100 levels in serum.
Neuron specific enolase:
The evidence for the predictive value of concentration of neuron specific enolase in adults and in children with TBI was strong. 12 studies which had evaluated NSE as a prognostic factor were reviewed; all but three studies (6,13) achieved significant associated between high levels of NSE and poor prognosis. Six studies were performed on children with traumatic brain injury (6, 11, 12) and seven studies on adults (13, 15, 16, 17, 20, 22, 23) 
Hyperphosphorylated neurofilament:
According to the studies, serum concentration of NF-H is a strong prognostic factor in children. Two studies (10,24) evaluated serum NF-H levels as a prognostic factor in TBI; Both studies performed on children in both studies, high levels associated with poor prognosis.
Ubiquitin C-Terminal Hydrolase:
5 articles that studied ( Table 2 ) serum levels of UCHL1 as a prognostic factor in TBI were reviewed. All of them studied the correlation between UCHL1 values and GOS except for a study conducted in 2012 by L.Papa et al. (25) in which outcome measures included the following:
(1) GCS scores obtained at presentation to the ED, (2) the presence of intracranial lesions on initial CT scan; and (3) the need for neurosurgical intervention (NSI). In this study, there was a significant relationship between all these three outcome measures, and levels of UCHL1 in adult patients with TBI. All of the other studies also found a significant correlation between high serum UCHL1 values and low GOS (unfavorable outcome).
TAU Protein
The evidence for the prognostic value of serum levels of TAU protein was Limited. Only one study (26) assessed serum levels of TAU protein as a prognostic factor in TBI. This study was conducted in 2008 by L. Nyle'n et al. (62) and reported high level of TAU protein levels as an independent risk factor for a poor outcome (GOS 1-3) (P=0.043). ROC evaluating the ability of serum t protein level to predict a poor outcome showed an area under the curve of 0.939 with 88% sensitivity and 94% specificity at a serum TAU protein level of 114.5 pg/mL.
Myelin basic protein
2 studies (6,11) evaluated the levels of myelin basic protein (MBP) in serum, as a TBI prognostic factor. In the study which was performed on children under 15 years of age with traumatic brain injury, a significant relation was found between levels of this protein and the GOS, 3-4 and 6-8 months after trauma (6) . In another study on children under 3 years who suffered a traumatic brain injury of varying intensities, high serum levels of MBP correlated with bad 6-month outcome which was measured by (Glasgow Outcome Scale using (GOS), Vineland Adaptive Behavior Scale (VABS) and the Intelligence Coefficient (IQ)
Glial Fibrillary Acidic Protein
The evidence for the prognostic value of serum levels of GFAP was strong. Seven studies (7, 10, 27, 28, 29, 30, 31) investigated serum GFAP levels as a prognostic factor and all of them reported the high values of GFAP correlates with poor prognosis. Four studies evaluated prognosis of TBI in children and reminding were performed on adults. In a study performed by S. Mondello and coworkers (27) in 2011, multivariate logistic regression analysis showed that of all the variables assessed, only UCH-L1 was an independent predictor of mortality at discharge and also strongly predicted deaths in 6 months after the damage predicted. Highly significant correlation between UCH-L1 and GFAP were found. GFAP did not have an additional contribution when UCH-L1 was already entered in the model. Similar predictive value for GFAP and UCH-L1 (c=0.93) was determined. The evidence for the prognostic value of BS levels was strong both in adults and in children with traumatic brain injury.
Lactate Dehydrogenase:
One study (53) evaluated Lactate Dehydrogenase levels as a prognostic factor of TBI. In both studies high levels were associated with poor prognosis. The evidence for the prognostic value of serum levels of LDH was strong. In V. Jain et al. study (68) in 2010, a significant relationship between serum LDH outcome after traumatic brain injury was found in patients with isolated brain trauma. In this study, the average increase in serum LDH was found in patients with a poor outcome and LDH levels increased continuously during the study period in both disabled and dead groups.
3.Plasma Osmolarity:
Two studies (34, 46) investigated plasma osmolarity as a prognostic factor. In a study by WhaSook Seo and HyunSoo Oh in 2009 (72) on patients with traumatic brain injury (and hemorrhagic stroke), 6 months after the trauma one of the physiologically significant predictors of cognitive abilities in patients with TBI was admission serum osmolarity (p= 0.01), but there was no significant association between plasma osmolarity mortality and functional disability. In Nelson DW et al. study (49) , poorer outcomes were observed with increasing osmolarity. According to these two studies, the evidence for the prognostic value plasma osmolarity was inconclusive.
4.Total cholesterol:
In WhaSook Seo and HyunSoo Oh study (72) (50) , correlation of albumin levels with outcome was like total cholesterol level. In Nelson DW et al. study (49) , low albumin relationship with poor outcome in patients with TBI was statistically significant. According to these studies, the evidence for the prognostic value of low albumin was also inconclusive.
6.Other biochemical tests:
Nelson DW study in 2005 (61) reported blood creatinine as an independent predictor of outcome after TBI. In study by Helmy et al. (50) , low magnesium only had a statistical relationship with outcome via at least two other variables and was designated as 'level 3' of the hierarchy. Hohl and colleagues in a study in 2012 (12) found that sodium in the blood of those who died after TBI was significantly higher. According to the above studies, the levels blood sodium was a strong prognostic factor of poor outcome in patients with traumatic brain injury, but the evidence for the prognostic value of the other variables was limited and uncertain.
Complete Blood Count (CBC):
Hemoglobin
Five studies (34, 43, 46, 48, 50) were reviewed which assessed Hb levels as a prognostic factor in TBI. In 3 of them (43, 48, 50) , low levels associated with poor prognosis. In two studies (34, 46) there was no significant correlations between Hb levels and prognosis. According to the studies, there was inconclusive evidence of relationship between Hb level and outcome in traumatic brain injury.
The leukocyte count
Three studies (38, 50, 55) were reviewed which assessed WBC count as a prognostic factor in TBI. None of them showed significant correlations between WBC levels and TBI prognosis. According to the studies, there was strong evidence of no relationship between WBC level and outcome in traumatic brain injury.
- 3 studies (23,38,58) assessed partial thromboplastin time (PTT) as a prognostic factor in TBI and two studies (38, 58) found a significant correlation between increased a PTT and poor outcome. So the evidence about prognosis prediction of PTT is strong. 3 studies (23,38,58) assessed platelet count as a prognostic factor in TBI and two studies (23,58) found a significant correlation between decreased platelet count and poor outcome. So the evidence about prognosis prediction of platelet count is strong. 2 studies (23,14) assessed D.dimer levels in serum as a prognostic factor in TBI and none of them found a significant correlation between its levels and outcome. Therefore, the evidence about that there is no relation between prognosis and levels of D.dimer is strong.
Only one study assessed each serum FDP levels (23) and serum VWF factor levels (31) found a significant correlation between them and outcome. Thus, the evidence about prognosis prediction of both of these is limited.
-Acute Phase Reactants:
1.Heat Shock Protein 70 (HSP 70):
2 studies (58,59) assessed HSP 70 levels in serum as a prognostic factor in TBI and both of them found a significant correlation between its levels and outcome. So the evidence about prognosis prediction of HSP70 is strong.
Pentraxin-PTX3
Only one study (54) investigated Pentraxin-PTX3 serum protein as a prognostic factor. In this study which was conducted in 2011 by Jackson da Silva Gullo et al., (20) increased PTX3 levels correlated with mortality (P<0.04). Thus, the evidence about prognosis prediction of PTX3 levels is limited.
-Inflammatory Factors:
3 studies (60,61,62) assessed some of the cytokines and inflammatory factors as prognostic factor in TBI. In Gopcevic et al. study (8) , plasma level of IL-8 was significantly lower in survivors (71.00 +/-14.17 pg/ml) than in non-survivors (111.26 +/-16.9 pg/ml). In Stein et al. study (60) , median daily IL-8 levels associated with poor outcome, the median serum values of other Cytokine levels (IL-1B, IL-6, IL-8, IL-10, and TNF-alfa) were not different between 2 groups (GOSE 1-4 vs 5-8). In Soares et al. study (58) , significant correlations of elevated serum levels of IL-10, but not TNF-α, with hospital mortality in patients with severe TBI were reported (p=0.01). Considering all these studies suggest that increased serum levels of IL-8 may be a strong prognostic factor but uncertain and limited predictive power of other inflammatory factors was seen. (42) , high estradiol and testosterone associated with mortality (p=0.026 and p=0.033, respectively). Significant effect of LH, FSH, progesterone on mortality through their association with estradiol (p=0.049). High estradiol was associated with worse outcomes. Stradiol mediated progesterone associations with GOS (p=0.045). Serum cortisol was not associated with mortality or GOS. In Llompart-Poue et al. study (37) , patients with low ACTH values (<9 pg/mL): statistically significant lower mortality (7% vs. 55%, p<0.0001) and low plasma ACTH in patient who survived, correlated with increased ICU length of stay (p<0.03). But no significant differences with baseline and stimulated serum cortisol after a high-dose corticotrophin stimulation test were seen. According to these studies, the serum cortisol strongly has no relation with outcome of patients with brain injury. And the evidence of the prognostic value of serum levels other hormones mentioned, was inclusive.
-Hormones
Matrix metalloproteinase 9:
In the study conducted by M. DeFazio et al. (17) a significant difference in the mean concentration of MMP-9 at admission (P=0.115) or in 24 h (P=0.535) was not found between the short term outcome groups. The study conducted by J. Copin et al.
(11) a significant relationship between serum MMP-9 levels and three-month GOSE in patients with severe TBI was not seen.
According to these studies, the serum MMP9 levels have no relation with outcome of patients with brain injury with moderate evidence.
α II-Spectrin Breakdown Product 145kDa:
Only one study (6) investigated serum SBDP145 level as a prognostic factor in TBI.
In one study (6) , unfavorable outcome was correlated with higher concentrations of SBDP145. According to this study, the evidence for the prognostic value of low SBDP145 was limited.
Circulating endothelial progenitor cells:
2 studies (66,67) were reviewed which assessed circulating endothelial progenitor cells as prognostic factor in TBI.
In Li Liu et al. study (9) , number of circulating EPCs was significantly lower in who died p<0.01 . In Gong D et al. study (69) , number of circulating EPCs was significantly correlated with GOS scores 6 months after TBI. Thus, the evidence for the predictive value of circulating endothelial progenitor cells was strong.
-Miscellaneous:
The studies of other factors, including serum oxidative stress parameters: thiobarbituric acid reactive species (TBARS) and carbonyl group (48), serum leptin (68) serum fibronectin CFn (65) and troponin cTnI were also reviewed which due to the low number of these studies for each factor, they can be a potential prognostic factors with limited evidence for TBI.
Conclusion
This systematic review summarized the results of 63 articles about the predictive value of various factors on prognosis after brain damage. Providing new information or explaining the findings in terms of pathophysiology is not the primary goal of a systematic review. Therefore, although relevant for clinicians, we were cautious not to speculate about underlying mechanisms or explanations for which no evidence was given in the included studies. Our study established strong evidence that serum concentration of S100 protein, neuron specific enolase, MBP, NF-H, GFAP, UCH-L1, blood glucose levels, serum levels of LDH, sodium level, prothrombin time, partial thromboplastin time, platelet count, D.dimer, HSP 70, serum levels of IL-8, number of circulating EPCs, and DNA levels in serum were predictors of post-TBI outcome. This study found strong evidence that WBC count and serum cortisol levels do not predict outcome. Moreover, moderate evidence was found that serum total cholesterol count do not predict outcome. Moderate evidence showed that high serum MMP9 levels predict poor outcome. For all other determinants the evidence was limited or inconclusive. Although these profiles are best evidence for prognosis after TBI, they seem to be of limited value; hence still we are not able to correct or prevent or treat some of these factors. Overall, it can be concluded that much information is needed on long term outcome moderate and severe traumatic brain injury.
Limitations of the review
It was very difficult to reach a consensus on all epidemiological findings across the 63 published studies because of critical differences in methods employed across the reports. Firstly, we searched studies published between the 2005 and 2014. It is possible that relevant publications before or after that time were not included in this review. However, we think that it would be inappropriate to include older studies in a review on prognostic factors, because there have been dramatic changes in measuring biomarkers concentrations and the treatment of traumatic injuries over the last years. Some of the included studies excluded penetrating head injury, other studies did not. Little information was given in the studies about how many patients had closed or open head injuries. It is not clear whether this has influenced our results. There was considerable heterogeneity for all outcomes of interest and in the time period over which outcome was evaluated. In the literature, different definitions for traumatic brain injury and the diagnostic methods are used. We decided to define brain injuries as the changes in brain function because of severe damage by an external force. We choose this fairly extensive definition is brain damage, so we would be able to enter many of the relevant studies. Furthermore, the populations studied were varied extensively in each literature from the other, in terms of gender, age, region and country in which they lived and were treated. Finally, we did not include studies published in languages other than English.
Recommendations:
Prediction of outcome after brain injury is not always straightforward, and there is always some uncertainty. Multiple factors may affect the outcome. Much of the literature available is written from an isolated neurological, neurosurgical or rehabilitation perspective. To improve outcome prediction, multidisciplinary research should take place, and knowledge should be integrated. Although several biomarkers of brain injury have been identified, continued research is required. A single biomarker may not have desired sensitivity and specificity for predicting outcome. Biomarkers, in combination with other clinical data, such as GCS and head CT scan, would maximize the accuracy. Future studies will be required to not only identify these biomarkers prognostic ability together with other factors. Serum levels of S100B, S100A1B and S100BB
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Venous blood samples
Patients with an unfavorable outcome had significantly increased maximum levels of S100B (p<0.05), S100A1B (p<0.01) and S100BB (p<0.01) Creatinine: an independent predictor of TBI outcome. Glucose, albumin, and osmolarity levels were also identified as predictors, depending on analysis method. A worse outcome related to increasing osmolarity. hemoglobin was not found significant when adjusted for post-resuscitation GCS Pelinka et al.
(29)
Germany. ? patiens, 92completing, age? Med 39 years. Inclusion: TBI with or without multiple trauma <12h before admission verified by CT
GOS
months 1 vs 4-5
Venous blood for GFAP and S100B daily GFAP &S100B: lower in GOS 4-5 than in GOS 1 (p < 0.0005). GFAP, but not S100B, was low-er in GOS 4-5 than in GOS 2-3 (p < 0.05) Salehpoor et al.
(15)
Iran, ? patients, 30completing. Age 9-90 years; Inclusion: Head trauma GCS≤8. All of them were in intensive care unit Exclusion: Multiple trauma patients were omitted Salehpoor, et al.
Author(s) Patient Characteristics Outcome Factor Result
Comments
The authors of this study included 63 reports including patients with 'different levels of TBI' and their 'outcome measure has been GCS after 6 months'. Even though design of this systematic review can bring up some information for the readers but there are issues important to be stressed regarding further similar future reviews; a) The question about different humoral factors effective upon the outcome of TBIs is an old issue for neurosurgeons treating emergency cases. A systematic review evaluating these elements is better to include prior publications with similar power-level from the literature and not only the bank of 8 years duration. b) For a systematic review to be of good conclusive remark, the studies with higher level of evidence and not, only cohort studies should be included in the chart. If there has been no such reports available, the power of the review would be low regarding the biases and threats to the validities and interpretation of the results. These errors are the results of flaw in either the method of selection of the studies or the procedures undertaken in gathering, interpreting and including the measures and/or disease information. c) To obviate the concordance of interpretation of information, the first step would be drawing the flow chart (lacking in this report).
To evaluate the possible inter-observer errors in a limited sample of cases, drawing the chart to measure the Kappa index (also lacking here) is helpful. Including a 'Prisma' model to coordinate between entry point, case management process and functional outcome is another way to empower a systematic review. d) A systematic review can be summarized in a 'funnel chart' till the readers could beware of the level of similarity/ concordance of the data extracted from all the references in a glance (lacking). e) Including all the levels of TBI in a systematic review includes quite a very large heterogeneous group of patients with all dissimilarities of the pathophysiological changes both in CNS and in the immune responses. Evaluating all the possible factors with or without independent and confounding impact upon a single outcome variable, can be very hard both for statistical analysis and for scientific interpretation of the results. f) For discussing a systematic review, it is not enough to select a single variable and highlight the points drawn from data extracted from a large table ( as it is included) but the most empowered and proven variables are better to be discussed only, otherwise misclassification of the information (regarding exposure and outcome categories) would be a common error. Anyhow, the kind researchers have done a great job preparing this excellent review for our readers, even though it wold be better to name it a 'narrative review of the literature'. , increased circulating cell-free DNA levels (DNA: 2 out of 2 studies) (1). They found two more strong evidence of decreased platelet count (2 out of 3 studies), and decreased number of circulating endothelial progenitor cells (EPCs: 2 out of 2 studies) in poor outcome of TBI patients. They stated moderate evidence for high serum MMP9 levels as a marker of poor outcome prediction for TBI. On the other hand, there was no relation between D-dimer level and poor outcome of moderate and severe TBI in the available two studies. I would acknowledge their extensive study and the importance of their study design. I believe the systematic reviews have high impact in promotion of science and literature. However, there are several important concerns in their study: Assessing quality and susceptibility to bias is essential when interpreting primary research and conducting systematic reviews for observational epidemiological studies such as cohort studies (2) . The recommended tool is STROBE guidelines for reporting observational epidemiological studies (3). For each included study in the systematic review of cohort studies, we have to perform quality assessment which has to be done based on the STROBE guideline not based on the consensus. It is the main difference between systematic review and narrative review. In the systematic review, any researcher can use guideline and evaluate if any study has high or low quality. However, in narrative review, an expert or a few experts perform their judgement based on the experience not based on the evidence. 
